Philips Healthcare unveiled two MR scanners on the RSNA 2008 exhibit floor: one at 3T, the other at 1.5T. Both emphasize productivity and clinical value, albeit by different means.
Philips Healthcare unveiled two MR scanners on the RSNA 2008 exhibit floor: one at 3T, the other at 1.5T. Both emphasize productivity and clinical value, albeit by different means.
The Achieva 3.0T TX expands the range of 3T applications possible with routine scanning through higher speed and better image quality using a novel technology dubbed MultiTransmit RF management. This technology automatically adjusts the RF signal to the specific body habitus and anatomy of the patient being scanned. The results, according to Philips, are higher acquisition speed, as well as better image quality and consistency. Together they offer new clinical possibilities for scanning the breast, liver, pelvis, and spine at 3T, according to the company.
Philips extended its current 1.5T platform with the Achieva SE, a scanner designed for budget-constrained customers. The scanner combines high-performance imaging and low capital cost through a sub-$1 million price tag, lower operating costs, and compact siting. The same basic platform drives both the Achieva SE and the high-end Achieva 1.5T A-Series, but the new product is repackaged without the more advanced clinical capabilities of the A-Series. Power-saving features reduce energy consumption -- and energy costs -- by up to 50%, according to Philips.
FDA Clears Virtually Helium-Free 1.5T MRI System from Siemens Healthineers
June 26th 2025Offering a cost- and resource-saving DryCool magnet technology, the Magnetom Flow.Ace MRI system reportedly requires 0.7 liters of liquid helium for cooling over the lifetime of the device in contrast to over 1,000 liters commonly utilized with conventional MRI platforms.
Multinational Study Reaffirms Value of Adjunctive AI for Prostate MRI
June 16th 2025The use of adjunctive AI in biparametric prostate MRI exams led to 3.3 percent and 3.4 percent increases in the AUC and specificity, respectively, for clinically significant prostate cancer (csPCa) in a 360-person cohort drawn from 53 facilities.
FDA Clears Enhanced MRI-Guided Laser Ablation System
June 5th 2025An alternative to an open neurosurgical approach, the Visualase V2 MRI-Guided Laser Ablation System reportedly utilizes laser interstitial thermal therapy (LITT) for targeted soft tissue ablation in patients with brain tumors and focal epilepsy.